A06-Clinical Oncology and Liquid Biopsy

Information
Members
Patents
Publications
Projects
Clinical trials

It is an active research group with stable connections with groups in the environment, at the regional and national level. Its intention is to link clinical and basic knowledge in a useful orientation for patients and for the evaluation of health services.

Research lines

Circulating and diverse tumor cells
Diet, physical exercise and cancer
Evaluation of results in Cancer
Response Modification by Mesenchymal Cells
Single and fractional dose radiosurgery
Radiotherapy with modified regimens (breast, lung, and others)
Variability in Oncology Practice (Radiation Therapy)

Research networks

CA17118 - Identifying Biomarkers Through Translational Research for Prevention and Stratification of Colorectal Cancer
CA21116 - Identification of biological markers for prevention and translational medicine in pancreatic cancer (TRANSPAN)

DIEGO DE MIGUEL PEREZ

JOSE ANTONIO LORENTE ACOSTA

IGNACIO PUCHE SANZ

ORCID

ROSARIO GUERRERO ROOF

More Information

MARIA JOSE SERRANO FERNANDEZ

ORCID

ISABEL TOVAR MARTIN

ORCID

MERCEDES ZURITA HERRERA

JOSE EXPOSITO HERNANDEZ

Inventors: VALERIA CECILIA DENNINGHOFF, MARIA JOSE SERRANO FERNANDEZ, ABEL GARCIA DIAZ, JOSE ANTONIO LORENTE ACOSTA, PEDRO J. ROMERO PALACIOS, BERNARDINO ALCÁZAR NAVARRETE
Title: EPIGENIC METHYLATION-BASED ALGORITHM FOR THE CLASSIFICATION OF RESPIRATORY DISEASES (COPD) - EPIMETRIC
Dress: RPISC2504041362649
Application date: 04 / 04 / 2025

Inventors: JOSE A. LORENTE, PEDRO J. ROMERO, JUAN JOSE DIAZ MONCHON, MARÍA PILAR MOLINA VALLEJO, MARÍA DEL CARMEN GARRIDO NAVAS, MARÍA JOSE SERRANO, BERNARDINO ALCAZAR NAVARRETE
Title: DETECTION IN CIRCULATING EPITHELIAL CELLS OF VIRUSES AND/OR BACTERIA CAUSING INFLAMMATORY INFECTIONS
Dress: P202330087
Application date: 07 / 02 / 2023

Inventors: FRANCISCO GABRIEL ORTEGA SANCHEZ; MARIA TERESA VALERO GRIÑAN; MARIA JOSE SERRANO FERNANDEZ; JOSE ANTONIO LORENTE ACOSTA; JOSE EXPOSITO HERNANDEZ; ROSARIO MARIA SANCHEZ MARTIN; JUAN JOSE DIAZ MOCHON
Title: IMMOBILIZATION CAPTURE OF EVS BY SPECIFIC BINDING OF A PEPTIDE TO ITS RECEPTOR T
Dress: P202330039
Application date: 20 / 01 / 2023

Inventors: MARÍA JOSÉ SERRANO FERNÁNDEZ, BERNARDINO ALCÁZAR NAVARRETE, PEDRO JOSÉ ROMERO, JUAN JOSÉ DÍAZ MOCHÓN, JOSÉ ANTONIO LORENTE ACOSTA, DIEGO DE MIGUEL PÉREZ
TitleISOLATION OF CIRCULATING EPITHELIAL CELLS IN PERIPHERAL BLOOD; DIAGNOSIS, PROGNOSIS AND PREDICTIVES
Dress: 17/513.080. USA
Application date: 28 / 10 / 2021

Inventors: MARÍA JOSÉ SERRANO FERNÁNDEZ
Title: ISOLATION AND CHARACTERIZATION OF LUNG CELLS.
DIAGNOSIS, PROGNOSIS AND PREDICTIVES
Dress: Apr 23552st,
Application date: 29 / 05 / 2020

Chou, T.Y.; Dacic, S; Wistuba, I; Beasley, M.B.; Berezowska, S; Chang, Y.C.; Chung, J.H.; Connolly, C; Han, Y.C. Hirsch, FR; Hwang, D.M.; Janowczyk, A; Joubert, P; Kerr, K.M.; Lin, D.M.; Minami, Y; Mino-Kenudson, M; Nicholson, A.G.; Papotti, M; Rekhtman, N; Roden, A.C.; von der Thuesen, JH; Travis, W; Tsao, M.S.; Yatabe, Y; Yeh, YC; Bubendorf, L; Chang, W.C.; Denninghoff, V; Tavora, FRF; Hayashi, T; Hoffman, P; Jain, D; Kim, T.J.; Lantuejoul, S; Le Quesne, J; Lopez-Rios, F; Matsubara, D; Noguchi, M; Radonic, T; Saqi, A; Schalper, K; Shim, H.S.; Sholl, L; Weissferdt, A; Cooper, WA

Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee

JOURNAL OF THORACIC ONCOLOGY, 2025;

FI: 20,8; D1

Zattoni, F; Gandaglia, G; van den Bergh, RCN; Marra, G; Valerio, M; Martini, A; Oliver, J; Puche-Sanzi, I; Rajwa, P; Maggi, M; Campi, R; Nicoletti, R; Amparore, D; De Cillis, S; Zhuang, J; Guo, H. Fuschi, A; Veccia, A; Ditonno, F; Pereira, LJP; Marquis, A; Barletta, F; Leni, R; Kasivisvanathan, V; Antonelli, A; Rivas, JG; Remmers, S; Roobol, M.J.; Briganti, A; Dal Moro, F; Novara, G.

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions – an EAU-YAU study enhancing prostate cancer detection

PROSTATE CANCER AND PROSTATIC DISEASES, 2025;

FI: 5,8; D1

Martínez, CG; Therapontos, S; Lorente, JA; Lucena, MA; Ortega, FG; Serrano, M.J.

Evaluating MicroRNAs as diagnostic tools for lymph node metastasis in breast cancer: Findings from a systematic review and meta-analysis

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025;

FI: 5,6; Q1

Alvarez-Salvago, F; Figueroa-Mayordomo, M; Molina-Garcia, C; Atienzar-Aroca, S; Pujol-Fuentes, C; Jimenez-Garcia, JD; Gutierrez-Garcia, P; Ching-Lopez, R; Medina-Luque, J

Exploring Predictors of Self-Perceived Cardiorespiratory Fitness ≥ 5 Years Beyond Breast Cancer Diagnosis: A Cross-Sectional Study

HEALTHCARE, 2025;

FI: 2,7; Q2

Haarkötter, C; Roca-Rada, X; Saiz, M; Vinueza-Espinosa, DC; Gálvez, X; Medina-Lozano, MI; Díaz-Ruiz, D; Alvarez, JC; Llamas, B; Lorente, JA; Austin, J

Exploring the Potential of Genome-Wide Hybridization Capture Enrichment for Forensic DNA Profiling of Degraded Bones

GENES, 2025;

FI: 2,8; Q2

Girl-Snoods, L; Cuenca-Lopez, S; Andres-Leon, E; Terron-Camero, LC; Cano-Gutierrez, B; Cozar, JM; Lorente, JA; Vazquez-Alonso, F; Martinez-Gonzalez, LJ; Alvarez-Cubero, MJ

Multi-omic study to unmask genes involved in prostate cancer development in a multi-case family

CANCER COMMUNICATIONS, 2024;

FI: 20,1; D1

Peressini, M; Garcia-Campelo, R; Massuti, B; Marti, C; Cobo, M; Gutiérrez, V; Domine, M; Fuentes, J; Majem, M; de Castro, J; Córdoba, JF; Diz, MP; Island, D; Esteban, E; Carcereny, E; Vila, L; Moreno-Vega, A; Ros, S; Moreno, A; García, FJ; Huidobro, G; Aguado, C; Cebey-López, V; Valdivia, J; Palmero, R; Lianes, P; López-Brea, M; Vidal, OJ; Provencio, M; Arriola, E; Baena, J; Herrera, M; Boat, H; Molero, M; Adradas, V; Ponce-Aix, S; Nuñez-Buiza, A; Ucero, A; Hernandez, S; Lopez-Rios, F; Count, E; Paz-Ares, L; Zugazagoitia, J

Spatially Preserved Multi-Region Transcriptomics Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

CLINICAL CANCER RESEARCH, 2024;

FI: 10,4; D1

M Blanco-Villar, J Expósito-Hernandez, Eulalia Navarro-Moreno, J M.ª López Martín, Adrian Particio Mota, Felipe Couñago.

Analyzing diagnosis and treatment wait time for lung cancer patients: key insight from a provincial registry study

Lung Cancer, 2024;

FI: 4,5; Q1

Reduzzi, C; Nicolo', E; Singhal, S; Venetis, K; Ortega-Franco, A; de Miguel-Perez, D; Dipasquale, A; Gouda, M.A.; Saldanha, E.F.; Kasi, PM; Jantus-Lewintre, E; Fusco, N; Malapelle, U; Gandara, D.R.; Rolfo, C; Serrano, MJ; Cristofanilli, M

Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024;

FI: 5,5; Q1

Marra, G; Lesma, F; Montefuscoa, G; Filippinia, C; Olivierb, J; Affentranger, A; Groggc, JB; Hermannsc, T; Afferid, L; Fankhauser, C.D.; Mattei, A; Malkiewicz, B; Scuderifg, S; Barletta, F; Hen, S; Antonellih, A; Zattonii, F; Dal Moro, F; Lieke, W; Soeterik, T; van den Bergh, RCN; Rajwak, P; Shariat, S.F.; Rodriguez-Sanchez, L; Nicoletti, R; Campi, R; Ahmed, M; Karnes, RJ; Ladurner, M; Heidegger, I; Briganti, A; Gontero, P; Gandaglia, G; Berchiche, W; Ploussard, G; Chiu, P; Dariane, C; Puche-Sanz, I; Kowalczyk, K; Bianchi, A; Magli, A; Tonetto, F; Facco, M; Young Academic Urologists Prostate Cancer Working Grp

Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort

EUROPEAN UROLOGY OPEN SCIENCE, 2024;

FI: 3,2; Q1

Ortega-Sanchez, FG; Theresa, V.; Widmann, T.; Regiart, M; Jerez-Salcedo, MT; Fernandez-Baldo, MA; by Miguel-Perez, D.

Microfluidic systems in extracellular vesicles single analysis. A systematic review

TRAC TRENDS IN ANALYTICAL CHEMISTRY, 2023;

FI: 13,100; D1

Ortega FG, Gomez GE, Boni C, García IC, Navas CG, D'vries RF, Molina Vallejos MP, Serrano MJ, Messina GA, Hernández JE, Fernández-Baldo MA

Microfluidic amperometric immunosensor based on porous nanomaterial towards claudin7 determination for colorectal cancer diagnosis

TALANTA, 2023;

FI: 6,1; D1

Barrios-Rodriguez, R; Garde, C; Perez-Carrascosa, FM; Exposito, J; Peinado, FM; Rodriguez, MF; Requena, P; Salcedo-Bellido, I; Arrebola, JP

Associations of accumulated persistent organic pollutants in breast adipose tissue with the evolution of breast cancer after surgery

SCIENCE OF THE TOTAL ENVIRONMENT, 2023;

FI: 9,8; D1

Ortega FG, Rio C, Jahn A, Gayá A, Calvo J, Monjo M, Montes-Worboys A, Molina-Molina M, Sala-Llinas E, Ramis JM

Antifibrotic Effects of Extracellular Vesicles From Umbilical Cord-Mesenchymal Stem Cells on Lung Myofibroblast Cells. Arch Bronconeumol

ARCHIVES DE BRONCONEUMOLOGIA, 2023;

FI: 8; Q1

Gonzalez-Martinez, C; Garrido-Navas, C; Alcaide-Lucena, M; Lorente, JA; Lopez-Hidalgo, J; Ortega, FG; Serrano, MJ

microRNAs signature in relapse metastasis and de novo metastasis of breast cancer. A systematic review

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023;

FI: 6,2; Q1

Aymard, C; Kanso, H; Serrano, MJ; Pagan, R; Noguer, T; Istamboulie, G

Development of a new dual electrochemical immunosensor for a rapid and sensitive detection of enrofloxacin in meat samples

FOOD CHEMISTRY, 2022;

FI: 9,231; D1

Rodriguez-Martinez, A; Simon-Saez, I; Perales, S; Garrido-Navas, C; Russo, A; De Miguel-Perez, D; Puche-Sanz, I; Alaminos, C; Ceron, J; Lorente, JA; Molina, MP; Gonzalez, C; Cristofanilli, M; Ortigosa-Palomo, A; Real, PJ; Rolfo, C; Serrano, M.J.

Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior.

THERANOSTICS, 2022;

FI: 11,6; D1

de Miguel-Perez, D; Russo, A; Arrieta, O; Ak, M; Barron, F; Gunasekaran, M; Mamindla, P; Lara-Mejia, L; Peterson, CB; Er, ME; Peddagangireddy, V; Buemi, F; Cooper, B; Manca, P; Lapidus, R.G. Hsia, RC; Cardona, AF; Naing, A; Kaushal, S; Hirsch, FR; Mack, P.C.; Serrano, MJ; Adamo, V; Colen, R.R.; Rolfo, C

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022;

FI: 12,658; D1

Martin-Way, D; Puche-Sanz, I; Cozar, JM; Zafra-Gomez, A; Gomez-Regalado, MDC; Morales-Alvarez, CM; Hernandez, AF; Martinez-Gonzalez, LJ; Alvarez-Cubero, MJ

Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer.

SCIENCE OF THE TOTAL ENVIRONMENT, 2022;

FI: 10,753; D1

Ortega, FG; Gomez, G.E.; Gonzalez-Martinez, C; Valero, T.; Exposito-Hernandez, J; Puche, I; Rodriguez-Martinez, A; Serrano, M. J.; Lorente, JA; Fernandez-Baldo, M.A.

A Novel, Quick, and Reliable Smartphone-Based Method for Serum PSA Quantification: Original Design of a Portable Microfluidic Immunosensor-Based System

CANCER, 2022;

FI: 6,575; Q1

Mustieles, V; Perez-Carrascosa, FM; Leon, J.; Lange, T.; Bonde, JP; Gomez-Pena, C; Artacho-Cordon, F; Barrios-Rodriguez, R; Olmedo-Requena, R; Exposito, J.; Jimenez-Moleon, JJ; Arrebola, J.P.

Adipose Tissue Redox Microenvironment as a Potential Link between Persistent Organic Pollutants and the 16-Year Incidence of Non-hormone-Dependent Cancer.

ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2021;

FI: 9,028; D1

Grinan-Lison, C; Blaya-Canovas, JL; Lopez-Tejada, A; Avalos-Moreno, M; Navarro-Ocon, A; Face, FE; Gonzalez-Gonzalez, A; Lorente, JA; Marchal, JA; Granados-Main, S

Antioxidants for the Treatment of Breast Cancer: Are We There Yet?

ANTIOXIDANTS, 2021;

FI: 6,313; D1

Miravitlles, M; Monteagudo, M; Solntseva, I; Alcázar, B.

Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study

ARCHIVES DE BRONCONEUMOLOGIA, 2021;

FI: 4,872; Q2

Alcazar-Navarrete, B; Garcia-Rio, F; Sanchez, G.; Mariscal, E.; Garcia, A; Cost, M; Uria, E.; Miravitlles, M.

Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021;

FI: 3,355; Q2

Garcia-Fumero, R; Fernandez-Lopez, C; Calleja-Hernandez, MA; Exposito-Hernandez, J.

Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

ONCOLOGICAL ACT, 2021;

FI: 4,089; Q3

Barrecheguren, M; Kostikas, K; Mezzi, K; Shen, S.V.; Alcázar, B; Soler-Cataluna, JJ; Miravitlles, M; Wedzicha, J.A.

COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population

THORAX, 2020;

FI: 10,844; D1

Soler-Cataluna, JJ; Alcazar, B; March, M; Perez, J; Miravitlles, M

Evaluation of Changes in Control Status in COPD An Opportunity for Early Intervention

CHEST, 2020;

FI: 8,308; D1

Olivares-Urbano, MA; Grinan-Lison, C; Zurita, M; del Moral, R; Rios-Arrabal, S; Artacho-Cordon, F; Arrebola, JP; Gonzalez, AR; Leon, J; Marchal, J.A.; Nunez, MI

Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020;

FI: 4,658; Q1

Soler-Cataluna, JJ; Alcázar, B; Miravitlles, M.

Clinical Control in COPD: A New Therapeutic Objective?

ARCHIVES DE BRONCONEUMOLOGIA, 2020;

FI: 4,957; Q1

Lopez-Campos, JL; Navarrete, BA; Miranda, JAR; Cosio, B.G.; de-Torres, JP; Celli, B; Jimenez-Ruiz, CA; Macario, C.C.

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients

INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020;

FI: 2,772; Q2

from Miguel-Perez, D; Bayarri-Lara, CI; Ortega, FG; Russo, A; Rodriguez, MJM; Alvarez-Cubero, MJ; Serrano, EM; Lorente, JA; Rolfo, C; Serrano, MJ

Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

CANCER, 2019;

FI: 6,162; Q1

Garrido-Navas, C; from Miguel-Perez, D; Exposito-Hernandez, J; Bayarri, C; Amezcua, V; Ortigosa, A; Valdivia, J; Guerrero, R; Puche, JLG; Lorente, JA; Serrano, MJ

Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents

CELLS, 2019;

FI: 5,656; Q1

Rodriguez-Martinez, A; from Miguel-Perez, D; Ortega, FG; Garcia-Puche, JL; Robles-Fernandez, I; Exposito, J; Martorell-Marugan, J; Carmona-Saez, P; Garrido-Navas, MD; Rolfo, C; Ilyine, H; Lorente, JA; Legueren, M; Serrano, MJ

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.

BREAST CANCER RESEARCH, 2019;

FI: 5,676; Q1

Romero-Palacios, PJ; Alcazar-Navarrete, B; Mochon, JJD; from Miguel-Perez, D; Hidalgo, JLL; Garrido-Navas, MD; Valenzuela, FQ; Lorente, JA; Serrano, MJ

Liquid biopsy beyond cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019;

FI: 5,012; Q1

Gonzalez-Herrera, L; Marquez-Ruiz, AB; Serrano, MJ; Ramos, V; Lorente, J.A.; Valenzuela, A.

mRNA expression patterns in human myocardial tissue, pericardial fluid and blood, and their contribution to the diagnosis of cause of death

FORENSIC SCIENCE INTERNATIONAL, 2019;

FI: 1,99; Q1

Cozar, JM; Robles-Fernandez, I; Martinez-Gonzalez, LJ; Pascual-Geler, M; Rodriguez-Martinez, A; Serrano, MJ; Lorente, J.A.; Alvarez-Cubero, M.J.

Genetic markers a landscape in prostate cancer

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2018;

FI: 5,205; D1

Salamanca-Fernandez, E; Rodriguez-Barranco, M; Chang-Chan, Y. L.; Redondo-Sanchez, D; Dominguez-Lopez, S; Bayo, E; Narankiewicz, D; Exposito, J; Sanchez, MJ

Thyroid Cancer Epidemiology in South Spain: a population-based time trend study

ENDOCRINE, 2018;

FI: 3,179; Q2

Puche-Sanz, I; Alvarez-Cubero, MJ; Pascual-Geler, M; Rodriguez-Martinez, A; Delgado-Rodriguez, M; Garcia-Puche, JL; Exposito, J; Robles-Fernandez, I; Entrala-Bernal, C; Lorente, J.A.; Cozar-Olmo, JM; Serrano, MJ

A comprehensive study of circulating tumor cells at the moment of prostate cancer diagnosis: biological and clinical implications of EGFR, AR and SNPs

ONCOTARGET, 2017;

FI: 5,168; Q1

Martin, IT; Avila, RD; Herrera, MZ; Arregui, G; Osorio-Ceballos, JL; Rojas, ES; Almansa, AH; Arrebola, JP; Rull, JP; Hernandez, JE; Ramirez, THE

Role of radiosurgery in the management of glomus tumors

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016;

FI: 2,76; D1

Arrebola, JP; Fernandez-Rodriguez, M; Artacho-Cordon, F; Garde, C; Perez-Carrascosa, F; Linares, I; Tovar, I; Gonzalez-Alzaga, B; Exposito, J; Torne, P; Fernandez, M.F.; Olea, N

Associations of persistent organic pollutants in serum and adipose tissue with breast cancer prognostic markers.

SCIENCE OF THE TOTAL ENVIRONMENT, 2016;

FI: 3,976; Q1

Linares, I; Molina-Portillo, E; Exposito, J; Baeyens, J.A.; Suarez, C; Sanchez, MJ

Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985-2012: a population-based study

CLINICAL & TRANSLATIONAL ONCOLOGY, 2016;

FI: 2,075; Q3

Artacho-Cordon, F; Fernandez-Rodriguez, M; Garde, C; Salamanca, E; Iribarne-Duran, L.M.; Torne, P; Exposito, J; Papay-Ramirez, L; Fernandez, M.F.; Olea, N; Arrebola, JP

Serum and adipose tissue as matrices for assessment of exposure to persistent organic pollutants in breast cancer patients.

ENVIRONMENTAL RESEARCH, 2015;

FI: 4,373; D1

Arrebola, JP; Belhassen, H; Artacho-Cordon, F; Ghali, R; Ghorbel, H; Boussen, H; Perez-Carrascosa, FM; Exposito, J; Hedhili, A; Olea, N.

Risk of female breast cancer and serum concentrations of organochlorine pesticides and polychlorinated biphenyls: A case-control study in Tunisia

SCIENCE OF THE TOTAL ENVIRONMENT, 2015;

FI: 4,099; D1

Gomez-Rio, M; Dardel, N.T.; Chinchilla, AS; Rodriguez-Fernandez, A; Granados, GO; Caro, R.L.; Herrera, MZ; Santos, CEC; Lardelli-Claret, P; Llamas-Elvira, JM

F-18-Fluorocholine PET / CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015;

FI: 5,383; D1

Arrebola, JP; Fernandez, M.F.; Martin-Olmedo, P; Bonde, J.P.; Martin-Rodriguez, JL; Exposito, J; Rubio-Dominguez, A; Olea, N

Historical exposure to persistent organic pollutants and risk of incident hypertension

ENVIRONMENTAL RESEARCH, 2015;

FI: 4,373; D1

Exposito, J; Linares, I; Castle, I; Martinez, M; Vargas, P; Herruzo, I; Medina, J.A.; Palaces, A; Bayo, E; Peracaula, F; Jaén, J; Sanchez, J.A.; Ortiz, M. J.

Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain

RADIATION ONCOLOGY, 2015;

FI: 2,546; Q2

Interaction between tumor cells and platelets: Impact on the epigenomic and phenotypic profile related to resistance to targeted therapy in patients with non-small cell lung cancer.(PLaCERT-2D))

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: PI25 / 00577

Execution time: 01/01/2026 - 31/12/2028

IP: MARIA JOSE SERRANO FERNANDEZ

Novel Molecular Diagnostic Device for Liquid Biopsy: Exploiting the Power of Acoustic Technology to Catch Tumor DNA (AT4LB)

Funder: STATE RESEARCH AGENCY

File number: CPP2024-011439

Execution time: 01/12/2025 - 30/11/2028

IP: MARIA JOSE SERRANO FERNANDEZ

IDENTIFICATION OF DETERMINANTS OF RESPONSE TO CHEMITRAPY/IMMUNOTHERAPY IN PATIENTS WITH SMALL LUNG CANCER

Funder: MUTUA MADRILEÑA FOUNDATION

File number: FMM-AP183262023

Execution time: 06/10/2023 - 05/10/2025

IP: MARIA JOSE SERRANO FERNANDEZ

IMNUNEXT

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: DTS23 / 00030

Execution time: 01/01/2024 - 31/12/2025

IP: FRANCISCO GABRIEL ORTEGA SANCHEZ

Subcontracting between UNIGE and FIBAO for the study of IL-38 charge in EVs Degree of contribution

Funder: UNIVERSITY OF GENEVA

File number: SERVICE CONTRACT

Running time: 2022 - 2023

IP: FRANCISCO GABRIEL ORTEGA SANCHEZ

Subsidies for the hiring of research personnel who hold the title of doctor or doctor in the field of health sciences and technologies (Project Identification of protein markers in extracellular vesicles (EVs) for the early diagnosis of lung cancer or pulmonary fibrosis Validation in patients with COPD or who have had COVID-19)

Funder: COUNCIL OF HEALTH AND FAMILIES

File number: RH-0074-2020

Execution time: 01/01/2021 - 12/12/2023

Proteomic Study of Extracellular Vesicles (EVs) for the diagnosis and monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD)

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: PI22 / 01275

Execution time: 01/01/2023 - 31/12/2025

IP: FRANCISCO GABRIEL ORTEGA SANCHEZ

Role of platelets in the induction and potentiation of malignant features in lung tumor disease

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: PI21 / 00786

Execution time: 01/01/2022 - 31/12/2024

IP: MARIA JOSE SERRANO FERNANDEZ

Integration of clinical information; digital imaging and genomics: towards the Optimization of Precision Oncology – INGENIO

Funder: Carlos III Health Institute - PRTR

File number: PMP21/00137

Execution time: 01/01/2022 - 31/12/2022

IP: MARIA JOSE SERRANO FERNANDEZ

APPROACH TO ORAL HEALTH AND QUALITY OF LIFE IN SURVIVORS OF HEAD AND NECK CANCER USING PHOTOBIOMODULATION THERAPY COMPLEMENTED WITH AN M-HEALTH SYSTEM. L3AXER STUDIO.

Funder: COUNCIL OF HEALTH AND FAMILIES

File number: PI-0187-2021

Execution time: 09/12/2021 - 08/12/2024

PI: ISABEL TOVAR MARTIN

Liquid biopsy applied to the analysis of the evolution of chronic obstructive pulmonary disease and its association with lung cancer. (Colorado Project)

Funder: COUNCIL OF HEALTH AND FAMILIES

File number: PIP-0192-2020

Execution time: 21/12/2020 - 20/12/2023

PI: BERNARDINO ALCAZAR NAVARRETE

PI-0439-2014 - Study of the Variability and Adequacy of the Local and Adjuvant Treatment of Breast Cancer, Sarcomas and Primary Brain Tumors, in Public Hospitals of Andalusia (Study Vara-2014)

Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

File number: PI-0439-2014

Execution time: 01/08/2015 - 31/07/2017

PI: ISABEL TOVAR MARTIN

ESR-17-12705 - MOLECULAR AND PHENOTYPIC PROFILES IN CIRCULATING TUMOR CELLS FROM OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS: ASSOCIATION WITH RELAPSE AND TREATMENT RESPONSE

Funder: ASTRAZENECA AB

File number: ESR-17-12705

Execution time: 01/01/2018 - 31/12/2018

IP: MARIA JOSE SERRANO FERNANDEZ

Translational Study on the Combined Use of Mesenchymal Stem Cells and Radiotherapy in the Treatment of Rectal Cancer

Funder: COUNCIL OF HEALTH

File number: PC-0252-2017

Execution time: 01/01/2018 - 31/12/2020

PI: ISABEL TOVAR MARTIN

Molecular and functional analysis of AR variants (AR-V7 and AR-V9) in platelets from patients with prostate cancer: prognostic and predictive markers of response to treatment.

Funder: CARLOS III HEALTH INSTITUTE - FEDER

File number: PI17 / 00989

Execution time: 01/01/2018 - 31/12/2020

IP: MARIA JOSE SERRANO FERNANDEZ

Identifying Biomarkers Through Translational Research for Prevention and Stratification of Colorectal Cancer

Funder: EUROPEAN COMMISSION

File number: COST2017-CA17118

Execution time: 01/10/2018 - 30/09/2022

IP: MARIA JOSE SERRANO FERNANDEZ

Ultra-hypofractionated salvage radiotherapy guided by PSMA PET-CT. Prospective study of safety, efficacy, and quality of life. “RULER”

Funder: BETURIA ANDALUSIAN FOUNDATION FOR HEALTH RESEARCH

Test type: OBSERVATIONAL STUDY WITH MEDICINES

Execution time: 27/05/2025 - 31/12/2030

IP: ROSARIO GUERRERO TEJADA

Randomized, double-blind, parallel-group study to compare the pharmacokinetics, efficacy, safety, and immunogenicity of JPB898 (proposed nivolumab biosimilar) and US-licensed, EU-authorized Opdivo® in combination with Yervoy® in treatment-naïve participants with advanced (unresectable/metastatic) melanoma.

Funder: HEXAL AG

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 27/01/2025 - 30/09/2027

PI: JAVIER VALDIVIA BAUTISTA

A randomized, controlled phase III study of IMC-F106C plus nivolumab versus nivolumab in HLA A*02:01-positive subjects with previously untreated advanced melanoma (PRISM-MEL-301)

Funder: IMMUNOCORE LIMITED

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 04/09/2024 - 15/12/2026

PI: JAVIER VALDIVIA BAUTISTA

Perioperative phase II and phase III trial of fianlimab and cemiplimab compared with an anti-PD1 alone in patients with resectable stage III and IV melanoma.

Funder: ICON CLINICAL RESEARCH LTD

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 11/11/2024 - 24/10/2030

PI: JAVIER VALDIVIA BAUTISTA

Perioperative phase II trial of fianlimab and cemiplimab in combination with chemotherapy versus cemiplimab in combination with chemotherapy in patients with resectable early-stage NSCLC (stages II to IIIB [N2]).

Funder: ICON CLINICAL RESEARCH LTD

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 26/11/2024 - 03/06/2029

PI: JAVIER VALDIVIA BAUTISTA

THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+).

Funder: MON CLINIC BARCELONA PRIVATE FOUNDATION

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 28/11/2023 - 30/09/2025

PI: BERNARDINO ALCAZAR NAVARRETE

Phase IIb clinical study evaluating the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone in participants with high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calm

Funder: JANSSEN-CILAG, SA

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 10/03/2023 - 30/03/2027

IP: IGNACIO PUCHE SANZ

A phase 3, randomized, multicenter study to evaluate the efficacy of TAR-200 in combination with cetrelimab compared with concomitant chemoradiotherapy in participants with non-retinal muscle-invasive bladder urothelial carcinoma (MIBC)

Funder: JANSSEN-CILAG, SA

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 22/03/2023 - 20/10/2028

IP: IGNACIO PUCHE SANZ

Randomized, double-blind, placebo-controlled, parallel-group, multicenter, Phase IIa trial to evaluate the efficacy and safety of AZD4831, over 12-24 weeks, in moderate to severe chronic obstructive pulmonary disease (COPD) (CRESCENDO)

Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA

Type of test: CLINICAL TRIAL WITH DRUGS

Execution time: 25/11/2022 - 31/07/2024

PI: BERNARDINO ALCAZAR NAVARRETE

“Multicenter, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC as adjunctive treatment in participants with COPD, experiencing frequent exacerbations and characterized by eosinophil levels

Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 26/07/2022 - 31/07/2024

PI: BERNARDINO ALCAZAR NAVARRETE

Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

Funder: GENENTECH INC

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 18/03/2022 - 30/08/2024

PI: BERNARDINO ALCAZAR NAVARRETE

Phase 2a, multicenter, parallel group, placebo-controlled, double-blind, randomized study to investigate the efficacy and safety of tezepelumab in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) (COURSE)

Funder: ASTRAZENECA AB

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 17/06/2022 - 30/03/2024

PI: BERNARDINO ALCAZAR NAVARRETE

Phase IIa, double-blind, randomized, parallel, placebo-controlled trial to investigate the effect of PBF-680 in conjunction with usual medication in subjects with moderate to severe COPD.

Financier: PALOBIOFARMA SL

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 20/06/2022 - 30/06/2023

PI: BERNARDINO ALCAZAR NAVARRETE

Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety of RO7486967 in Patients With Chronic Obstructive Pulmonary Disease

Financier: F. HOFFMANN-LA ROCHE LTD

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 20/01/2022 - 30/12/2022

PI: BERNARDINO ALCAZAR NAVARRETE

Phase II, multicenter, randomized, parallel-group study to evaluate the safety, tolerability, and pharmacokinetics of a second-generation VIR-7831 in non-hospitalized participants with mild coronavirus disease 2019 (COVID-19).

Funder: VIR BIOTECHNOLOGY INC

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 21/06/2021 - 28/02/2022

PI: BERNARDINO ALCAZAR NAVARRETE

Historical values vs. Current blood eosinophils in patients with severe uncontrolled asthma: predictive ability of future risks. ENEAS II study.

Funder: SPANISH LUNG FOUNDATION - RESPIRA

Type of test: INDEPENDENT POST-AUTHORIZATION STUDY

Execution time: 17/09/2020 - 30/04/2021

PI: BERNARDINO ALCAZAR NAVARRETE

Multicenter, Randomized, Double-Blind, Parallel Group Trial to Evaluate Efficacy and Safety of PT009 Compared to PT005 in COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD

Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA

Type of test: COMMERCIAL CLINICAL TRIAL

Execution time: 22/11/2016 - 30/08/2018

PI: BERNARDINO ALCAZAR NAVARRETE

A06-Clinical Oncology and Liquid Biopsy

Research lines

Research networks

DIEGO DE MIGUEL PEREZ

ABEL GARCIA DIAZ

ROSARIO CHING LOPEZ

Manuel Luis Blanco Villar

JOSE ANTONIO LORENTE ACOSTA

IGNACIO PUCHE SANZ

ROSARIO GUERRERO ROOF

MARIA JOSE SERRANO FERNANDEZ

ISABEL TOVAR MARTIN

MERCEDES ZURITA HERRERA

JOSE EXPOSITO HERNANDEZ

Research